ASCO 2026 | Real-world treatment patterns and OS in R/M HNSCC following ICI and platinum-based chemotherapy
Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses the real-world patterns and overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) following iimmune checkpoint inhibitor and platinum-based chemotherapy, highlighting that the median OS for patients with HPV-negative head and neck cancer is approximately six months, and nine months for those with HPV-positive disease, after progressing on frontline treatment. Dr Rosenberg notes that these results are sobering and indicate a significant unmet need for improved therapies in this population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
